Publication | Open Access

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

MelanomaImmunologyTherapeutic VaccineAdjuvant TreatmentAutoimmunityImmunomodulationDermatologyImmunotherapyMedicineCell Transplantation